Surrozen (SRZN) Research & Development (2020 - 2026)
Surrozen (SRZN) posted quarterly Research & Development of $9.3 million for Q1 2026, up 42.24% year-over-year from $6.6 million in Q1 2025, and up 3.75% quarter-over-quarter from $9.0 million in Q4 2025.
Surrozen (SRZN) Research & Development (2020 - 2026) Analysis & Trends
Surrozen's Research & Development history runs 7 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Research & Development rose 42.24% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $32.1 million (up 43.18% YoY), while the FY2025 annual figure was $29.4 million, up 38.96% from the prior year.
- Research & Development for Q1 2026 stood at $9.3 million, up from $9.0 million in the prior quarter.
- The five-year high for Research & Development was $9.6 million in Q2 2022, with the low at $5.2 million in Q3 2024.
- The 5-year median for Research & Development is $6.9 million (2023), against an average of $7.3 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 82.75% in 2022, then jumped 68.06% in 2025.
- Surrozen's Research & Development stood at $9.4 million in 2022, then sank by 35.41% to $6.1 million in 2023, then retreated by 12.22% to $5.4 million in 2024, then surged by 68.06% to $9.0 million in 2025, then increased by 3.75% to $9.3 million in 2026.
- Business Quant data shows SRZN's Research & Development at $9.3 million in Q1 2026, $9.0 million in Q4 2025, and $7.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 8.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.48 Mn |
| Mar 31, 2026 | 9.33 Mn |
| Dec 31, 2025 | 8.99 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | 6.56 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Sep 30, 2024 | 5.20 Mn |
| Jun 30, 2024 | 5.34 Mn |
| Mar 31, 2024 | 5.25 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 6.11 Mn |
| Jun 30, 2023 | 6.94 Mn |
| Mar 31, 2023 | 8.09 Mn |
| Dec 31, 2022 | 9.44 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Jun 30, 2022 | 9.58 Mn |
| Mar 31, 2022 | 9.37 Mn |
| Dec 31, 2021 | 10.89 Mn |
| Sep 30, 2021 | 50.00 Mn |